| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Clontech Laboratories, Inc. |
| 1020 East Meadow Circle, Palo Alto, CA 94303 * (650) 424-8222 |
| Business Description | The company develops, manufactures and markets products for life science research. The company's products enable scientists to identify genes, study how cells are regulated by genes and search for drugs that can treat diseases. |
|
Filing Information IPO has been | |||
| To Trade As | CLON (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 02/19/1999 |
| Domestic Shares Filed | 3,750,000 | Filing Range | $14.00 - $16.00 |
| Foreign Shares Filed | 0 | Offering Amount | $56,250,000 |
| Company Shares | 3,750,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| BT Alex Brown | Lead Manager | (410) 727-1700 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 439-3626 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1994 | 12/31/1995 | 12/31/1996 | 12/31/1997 | 12/31/1998 | ||
| Revenues | 15.316 | 17.351 | 27.164 | 36.802 | 47.811 | - | - |
| Income from Oper. | 2.066 | 1.511 | 5.372 | 6.201 | 6.891 | - | - |
| Net Income | 1.306 | 0.871 | 3.441 | 3.673 | 4.046 | - | - |
| E.P.S | 0.110 | 0.070 | 0.290 | 0.310 | 0.340 | - | - |
| Revenue Growth (%) | 13.29 | 56.56 | 35.48 | 29.914 | - | ||
| Net Income Growth (%) | -33.31 | 295.06 | 6.74 | 10.16 | - | ||
| Oper. Profit Margin (%) | 13.49 | 8.71 | 19.78 | 16.85 | 14.41 | - | - |
| Net Profit Margin (%) | 8.53 | 5.02 | 12.67 | 9.98 | 8.46 | - | - |
| Cash Flow - Oper. | 3.84 | - | - | ||||
| Cash Flow - Inv. | -0.36 | - | - | ||||
| Cash Flow - Fin. | 1.20 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/1998 | Financial Ratios | ||||
| Total Assets | 40.06 | Current Assets | 30.80 | Current Ratio | 2.55 |
| Total Liab. | 22.80 | Current Liab. | 12.09 | Debt Ratio | 56.91% |
| Total Equity | 17.26 | Working Cap. | 18.72 | Debt to Equity Ratio | 1.32 |
| Cash | 15.53 | Return on Assets | 10.10% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for retirement of debt, expansion of manufacturing capacity, expansion of sales and marketing infrastructure, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Latham & Watkins |
| Registrar/Transfer Agent | EquiServe |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |